Recent news on Tirofiban

Medicure's Aggrastatr Highlighted in Expert Opinion Journal  -  Apr 20, 2007
PharmaLive.com (press release),..."The available data suggests that high-dose bolus tirofiban may be as effective and safe as abciximab in patients undergoing PCI.

The Timing Of Administration Of Platelet-Inhibiting Drugs  -  Feb 19, 2007
Medical News Today (press release),..."Furthermore, the upstream use of platelet glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors (tirofiban or eptifibatide) prior to angiography in patients with

MGI PHARMA Reports Fourth Quarter and Full Year 2006 Financial Results  -  Feb 8, 2007
PharmaLive.com (press release),...acquired in process research and development expenses, transactions costs related to the divestiture of Aggrastat(R) (tirofiban hydrochloride) Injection

Effects of GP IIb/IIIa Inhibitors on Vascular Inflammation ...  -  Jan 17, 2007
HeartZine,Abciximab and the small-molecule GP IIb/IIIa inhibitors (eptifibatide, tirofiban) have separate, distinct binding sites on the GP IIb/IIIa receptor complex.

Medicure Announces Second Quarter Fiscal 2007 Financial Results  -  Jan 12, 2007
PharmaLive.com (press release),The Company launched its US sales organization to support the sales and marketing efforts for AGGRASTATR (tirofiban). * The Company established its wholly

Medicure Completes US$25.9 Million Private Placement  -  Dec 28, 2006
Genetic Engineering News (press release),The meta-analysis suggests that Single High-Dose Bolus tirofiban may be as effective as abciximab in patients undergoing PCI with a comparable safety

Primary PCI for Myocardial Infarction with ST-Segment Elevation  -  Jan 3, 2007
New England Journal of Medicine (subscription),Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293:2109-2117.

Affimed´s Fully Human Anti Thrombosis Antibody Shows in Vivo ...  -  Dec 4, 2006
PharmaLive.com (press release),Australia demonstrated that the antithrombotic effect is comparable to the clinically used conformation-unspecific GPIIb/GPIIIa blockers tirofiban and

Medicure Announces New Aggrastat'R' Data to be Presented at 2006 ...  Nov 6, 2006
...company, today announced that an abstract outlining a recently completed meta-analysis comparing Single High-Dose Bolus AGGRASTAT ® (tirofiban) and ReoPro ... -CCNMatthews (press release), Medicure Announces New Aggrastat Data to Be Presented at 2006 ...  Nov 6, 2006
...company, today announced that an abstract outlining a recently completed meta-analysis comparing Single High-Dose Bolus AGGRASTATR (tirofiban) and ReoProR ... -PharmaLive.com (press release), Medicure Announces Financial Results for Fiscal First Quarter 2007  Oct 12, 2006
The Company announced that acquisition of the exclusive US rights to AGGRASTAT Injection (tirofiban hydrochloride) from MGI PHARMA, INC. ... -PharmaLive.com (press release), Medicure Announces Launch of US Sales Organization  Oct 11, 2006
...company, today announced the launch of its US sales organization to support the sales and marketing efforts for AGGRASTAT® injection (tirofiban hydrochloride ... -Market Wire (press release) MGI PHARMA Reports Third Quarter 2006 Financial Results  Oct 18, 2006
...includes $1.0 million of amortization of product acquisition intangible assets, $0.5 million of Aggrastat® injection (tirofiban hydrochloride) transaction ... -Business Wire (press release), Roadmap To Integrin Activation Created By UCSD Researchers  Sep 21, 2006
Direct inhibitors of GPIIb-IIIa binding include antithrombotics such as eptifibatide (Integrelin), abciximab (Reopro), and tirofiban (Aggrestat), drugs that ... -Medical News Today

Medicure Announces New Aggrastatr Data at 2006 Scientific Sessions ...  -  Nov 14, 2006
PharmaLive.com (press release),The study results demonstrated an event rate for the 30-day composite of 6.1% with tirofiban and 7.3% with abciximab (p=0.46). There were no significant

Affimed´s Fully Human Anti Thrombosis Antibody Shows in Vivo ...  -  Dec 4, 2006
PharmaLive.com (press release),Australia demonstrated that the antithrombotic effect is comparable to the clinically used conformation-unspecific GPIIb/GPIIIa blockers tirofiban and

Medicure Reports Highlights and Financial Results for Fiscal 2006  Aug 15, 2006
Subsequent to fiscal 2006, the Company acquired the US rights to its first commercial product, AGGRASTAT ® Injection (tirofiban hydrochloride) in the US for ... -CCNMatthews

Medicure Acquires US Rights to Aggrastat'R' from MGI PHARMA, INC.  Aug 9, 2006
...biopharmaceutical company, today announced that the Company has acquired the exclusive US rights to AGGRASTAT® Injection (tirofiban hydrochloride) from MGI ... -Market Wire

Medicure Acquires Marketed CV Drug Aggrastat From MGI  Aug 9, 2006
Launched in the US in 1998, Aggrastat (tirofiban hydrochloride) has had modest sales because it has lacked a sustained sales support the past several years. ... -BioWorld Online

Medicure Acquires US Rights To Aggrastat From MGI Pharma  Aug 9, 2006
Medicure Inc. (MCU) has acquired the exclusive US rights to AGGRASTAT Injection (tirofiban hydrochloride) from MGI Pharma Inc. (MOGN). ... -Easy Bourse (Communiqués de presse)

New Trials of Antithrombotic Therapy for ACS -- ACC 2006  Jul 21, 2006
...randomized high-risk UA/NSTEMI patients to 1 of 3 arms: in 2 of the 3 arms patients received a GP IIb/IIIa inhibitor, either eptifibatide or tirofiban, in the ... -Medscape (subscription)

MGI PHARMA Reports Second Quarter 2006 Financial Results  Jul 19, 2006
Injection, the inclusion of sales of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) and Aggrastat(R) (tirofiban hydrochloride) Injection following ... -Business Wire



Clopidogrel Treatment Prior to Percutaneous Coronary Intervention  Apr 4, 2006
Abciximab, eptifibatide, and tirofiban were studied in several placebo-controlled trials involving nearly 17 000 patients undergoing nonemergent PCI. ... - Journal of American Medical Association (subscription)

Recommendations for Anticoagulated Patients Undergoing Image ...  Mar 21, 2006
This class of antiplatelet drugs includes abciximab (ReoPro), eptifibatide (Integrilin), and tirofiban (Aggrastat). Normal platelet ... - Am J Neuroradiology (subscription)

Drug-eluting and absorbable stents push interventional frontiers  Mar 13, 2006
...centers in 17 countries performed a second comparison, randomly assigning 9,200 patients to receive either upfront GPI (eptifibatide or tirofiban) in the ... - EurekAlert



Thrombolytic Treatment Before Stenting Linked to Increased ...  Feb 14, 2006
...in mortality for patients pre-treated with glycoprotein IIb/IIIa inhibitors such as ReoPro (abciximab), Integrilin (eptifibatide), and Aggrastat (tirofiban). ... - MedPage Today,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional